Premium
Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
Author(s) -
Basali Diana,
Chakraborty Rajshekhar,
Rybicki Lisa,
Rosko Nathaniel,
Reed Janice,
Karam Maryann,
Schlueter Kristen,
Dysert Hayley,
Kalaycio Matt,
Valent Jason
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16454
Subject(s) - venetoclax , medicine , multiple myeloma , oncology , hematology , refractory (planetary science) , intensive care medicine , leukemia , chronic lymphocytic leukemia , astrobiology , physics
Summary The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti‐apoptotic protein BCL‐2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax‐based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non‐haematologic toxicities, most commonly gastrointestinal upset, were observed.